GIPET-1 is currently used in tablet form of insulin with three different coatings and has been studied for its pharmacokinetics and pharmacodynamics properties towards the treatment of diabetes mellitus and is currently the subject of a Phase I clinical trial (NCT01931137) [170,171,172]. Here, INS is linked to diabetes mellitus.